FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230754783> ?p ?o ?g. }

• W4230754783 endingPage "85" @default.
• W4230754783 startingPage "85" @default.
• W4230754783 abstract "Abstract Introduction Alkylating agent-rituximab combinations are a current standard of care for patients with iNHL. Most iNHL will eventually become refractory to current therapies. Particularly, once iNHL becomes “double-refractory” to rituximab + alkylating agents, there are few data available on beneficial therapeutic options and development of novel therapies is essential for this patient population. PI3K-delta signaling is critical for activation, proliferation and survival of B cells, and is hyperactive in many B-cell malignancies. Idelalisib, a selective oral inhibitor of PI3Kδ, demonstrated considerable activity in recurrent iNHL in a phase 1 trial (Kahl, ICML 2011). We thus evaluated idelalisib in a phase 2 trial for patients with double-refractory iNHL, an area of unmet medical need. We present mature response data and extended follow-up of this study. Methods Eligible iNHL patients (pts) included those with measurable disease who were refractory to both rituximab and an alkylating agent. Refractory status was defined as lack of response to, or progression of lymphoma within 6 months of completion of therapy, documented by imaging. Idelalisib 150 mg PO BID was administered continuously until disease progression or intolerance. Responses were evaluated by an independent review committee, using standard criteria (Cheson, 2007). The new data cutoff date for this analysis was June 2013, 8 months after the last patient enrolled. Results Enrolled pts (N=125) had a median age of 64 years [range 33-87] and were 64% male. Indolent NHL subtypes included follicular lymphoma (FL) n=72 (58%), small lymphocytic lymphoma (SLL) n=28 (22%), marginal zone lymphoma (MZL) n=15 (12%) and lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) n=10 (8%). The median number of prior therapies was 4 [range 2-12], most common regimens included bendamustine/rituximab (BR) (n=60) and rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) (n=56) and 14 pts (11%) had a prior autologous transplant. 81 pts (65%) had prior bendamustine, of which 61/81 (75%) were refractory. 112 pts (90%) were refractory to their last regimen, and 99 pts (79%) were refractory to ≥2 regimens. Median time since completion of last regimen was 3.9 months. At baseline, pts had elevated LDH (30%), bulky disease >7 cm (26%), anemia ≥grade 1 (51%), neutropenia ≥ grade 1 (24%), and thrombocytopenia ≥grade 1 (34%). With a median follow up 9.4 months, the overall response rate (ORR) was 57% (95% CI = 47.6, 65.6) with 71 responders, comprising 7 CRs (6%), 63 PRs (50%), and 1 minor response (MR) in a WM pt. There were 42 pts with stable disease (SD) (33%). 90% of pts experienced some decrease in tumor burden (Figure 1). Median time to response was 1.9 months (range 1.6-8.3), median time to CR was 3.7 months (range 1.9-12). ORR for iNHL subtypes was: FL (54%), SLL (61%), LPL/WM (80%), and MZL (47%). ORR for bendamustine refractory pts was 59%. ORR for pts with <4 /≥4 prior therapies was 50%/62%, and for bulky disease <7cm/≥7cm was 57/57%. Among responders, median DOR was 12.5 months. Median PFS for all pts was 11.0 months and median overall survival was 20.4 months. The most common adverse events were (total%/≥ grade 3%) diarrhea (43/13), fatigue (30/2), nausea (30/2), cough (29/0), pyrexia (28/2), dyspnea (18/3), rash (13/2), and pneumonia (11/7). Based on central laboratory measurements, Grade ≥3 ALT/AST elevations occurred in 16 pts (13%). Drug was held for these pts, and 11/14 pts (79%) were re-treated without recurrence of ALT/AST elevation. Grade ≥3 neutropenia occurred in 27%, thrombocytopenia in 6%, and anemia in 2%. 20% of pts have discontinued therapy due to adverse events. Conclusions Idelalisib was well tolerated, had an acceptable safety profile, and was highly effective in this double-refractory iNHL population with an ORR of 57%. The ORR was consistent across all subgroups, regardless of disease histology, number of prior regimens, refractoriness to bendamustine, or tumor bulk. With continued administration of idelalisib, responses were durable beyond one year, substantially exceeding the median DOR for the last prior therapy. Mature response data demonstrate that idelalisib can provide clinical benefit to patients with the unmet medical need of double-refractory iNHL. Disclosures: Gopal: Gilead Sciences: Research Funding. Off Label Use: Idelalisib is a PI3K-delta inhibitor currently in phase III trials for multiple hematologic malignancies. Kahl:Gilead Sciences: Advisory Board Other, Research Funding. De Vos:Gilead Sciences: Advisory Board Other, Research Funding. Wagner-Johnston:Gilead Sciences: Research Funding. Schuster:Gilead Sciences: Research Funding. Blum:Gilead Sciences: Research Funding. Jurczak:Gilead Sciences: Research Funding. Flinn:Gilead Sciences: Research Funding. Flowers:Gilead Sciences: Research Funding. Martin:Gilead Sciences: Research Funding. Viardot:Gilead Sciences: Research Funding. Goy:Gilead Sciences: Research Funding. Davies:Gilead Sciences: Research Funding. Zinzani:Gilead Sciences: Research Funding. Dreyling:Gilead Sciences: Research Funding. Holes:Gilead Sciences: Employment. Li:Gilead Sciences: Employment. Dansey:Gilead Sciences: Employment. Godfrey:Gilead Sciences: Employment. Salles:Gilead Sciences: Research Funding." @default.
• W4230754783 created "2022-05-11" @default.
• W4230754783 creator A5000959540 @default.
• W4230754783 creator A5001765276 @default.
• W4230754783 creator A5004025497 @default.
• W4230754783 creator A5015361329 @default.
• W4230754783 creator A5027453053 @default.
• W4230754783 creator A5027975872 @default.
• W4230754783 creator A5042317118 @default.
• W4230754783 creator A5046049357 @default.
• W4230754783 creator A5053429973 @default.
• W4230754783 creator A5056235620 @default.
• W4230754783 creator A5056946123 @default.
• W4230754783 creator A5067716137 @default.
• W4230754783 creator A5069054551 @default.
• W4230754783 creator A5080630441 @default.
• W4230754783 creator A5081213752 @default.
• W4230754783 creator A5082892912 @default.
• W4230754783 creator A5086354986 @default.
• W4230754783 creator A5088132556 @default.
• W4230754783 creator A5089882481 @default.
• W4230754783 creator A5091882595 @default.
• W4230754783 date "2013-11-15" @default.
• W4230754783 modified "2023-10-01" @default.
• W4230754783 title "Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)" @default.
• W4230754783 doi "https://doi.org/10.1182/blood.v122.21.85.85" @default.
• W4230754783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24870874" @default.
• W4230754783 hasPublicationYear "2013" @default.
• W4230754783 type Work @default.
• W4230754783 citedByCount "10" @default.
• W4230754783 countsByYear W42307547832014 @default.
• W4230754783 countsByYear W42307547832015 @default.
• W4230754783 countsByYear W42307547832016 @default.
• W4230754783 countsByYear W42307547832017 @default.
• W4230754783 countsByYear W42307547832019 @default.
• W4230754783 countsByYear W42307547832020 @default.
• W4230754783 crossrefType "journal-article" @default.
• W4230754783 hasAuthorship W4230754783A5000959540 @default.
• W4230754783 hasAuthorship W4230754783A5001765276 @default.
• W4230754783 hasAuthorship W4230754783A5004025497 @default.
• W4230754783 hasAuthorship W4230754783A5015361329 @default.
• W4230754783 hasAuthorship W4230754783A5027453053 @default.
• W4230754783 hasAuthorship W4230754783A5027975872 @default.
• W4230754783 hasAuthorship W4230754783A5042317118 @default.
• W4230754783 hasAuthorship W4230754783A5046049357 @default.
• W4230754783 hasAuthorship W4230754783A5053429973 @default.
• W4230754783 hasAuthorship W4230754783A5056235620 @default.
• W4230754783 hasAuthorship W4230754783A5056946123 @default.
• W4230754783 hasAuthorship W4230754783A5067716137 @default.
• W4230754783 hasAuthorship W4230754783A5069054551 @default.
• W4230754783 hasAuthorship W4230754783A5080630441 @default.
• W4230754783 hasAuthorship W4230754783A5081213752 @default.
• W4230754783 hasAuthorship W4230754783A5082892912 @default.
• W4230754783 hasAuthorship W4230754783A5086354986 @default.
• W4230754783 hasAuthorship W4230754783A5088132556 @default.
• W4230754783 hasAuthorship W4230754783A5089882481 @default.
• W4230754783 hasAuthorship W4230754783A5091882595 @default.
• W4230754783 hasConcept C121332964 @default.
• W4230754783 hasConcept C126322002 @default.
• W4230754783 hasConcept C142424586 @default.
• W4230754783 hasConcept C143998085 @default.
• W4230754783 hasConcept C203014093 @default.
• W4230754783 hasConcept C2777058707 @default.
• W4230754783 hasConcept C2777938653 @default.
• W4230754783 hasConcept C2778461978 @default.
• W4230754783 hasConcept C2779260929 @default.
• W4230754783 hasConcept C2779338263 @default.
• W4230754783 hasConcept C2779878957 @default.
• W4230754783 hasConcept C2780653079 @default.
• W4230754783 hasConcept C2908647359 @default.
• W4230754783 hasConcept C535046627 @default.
• W4230754783 hasConcept C71924100 @default.
• W4230754783 hasConcept C87355193 @default.
• W4230754783 hasConcept C99454951 @default.
• W4230754783 hasConceptScore W4230754783C121332964 @default.
• W4230754783 hasConceptScore W4230754783C126322002 @default.
• W4230754783 hasConceptScore W4230754783C142424586 @default.
• W4230754783 hasConceptScore W4230754783C143998085 @default.
• W4230754783 hasConceptScore W4230754783C203014093 @default.
• W4230754783 hasConceptScore W4230754783C2777058707 @default.
• W4230754783 hasConceptScore W4230754783C2777938653 @default.
• W4230754783 hasConceptScore W4230754783C2778461978 @default.
• W4230754783 hasConceptScore W4230754783C2779260929 @default.
• W4230754783 hasConceptScore W4230754783C2779338263 @default.
• W4230754783 hasConceptScore W4230754783C2779878957 @default.
• W4230754783 hasConceptScore W4230754783C2780653079 @default.
• W4230754783 hasConceptScore W4230754783C2908647359 @default.
• W4230754783 hasConceptScore W4230754783C535046627 @default.
• W4230754783 hasConceptScore W4230754783C71924100 @default.
• W4230754783 hasConceptScore W4230754783C87355193 @default.
• W4230754783 hasConceptScore W4230754783C99454951 @default.
• W4230754783 hasIssue "21" @default.
• W4230754783 hasLocation W42307547831 @default.
• W4230754783 hasLocation W42307547832 @default.
• W4230754783 hasOpenAccess W4230754783 @default.
• W4230754783 hasPrimaryLocation W42307547831 @default.
• W4230754783 hasRelatedWork W1970884884 @default.
• W4230754783 hasRelatedWork W1997629499 @default.

• next